E. Gorina

发表

Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.

F. Cordón, F. Auquer, E. Gorina, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Design of IPF Clinical Trials in the Era of Approved Therapies.

F. Martinez, J. Stauffer, L. Richeldi, 2019, American journal of respiratory and critical care medicine.

Late Breaking Abstract - Responder phenotyping using functional respiratory imaging (FRI) in IPF patients treated with anti-CGTG monoclonal antibody FG3019

J. Goldin, W. Vos, C. V. Holsbeke, 2017 .

Late Breaking Abstract - Assessment of disease progression in IPF patients using Functional Respiratory Imaging (FRI)

J. Goldin, W. Vos, C. V. Holsbeke, 2017 .

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

G. Raghu, J. Goldin, M. Scholand, 2019, The Lancet. Respiratory medicine.

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

G. Raghu, D. Khanna, A. Fischer, 2016, The Journal of Rheumatology.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

S. Nathan, D. Spirig, M. Glassberg, 2016, European Respiratory Journal.

Results of an orthopaedic survey in young patients with severe haemophilia in Spain

J. Aznar, M. Quintana, F. Querol, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

The orthopaedic status of severe haemophiliacs in Spain

J. Aznar, F. Querol, E. Gorina, 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

H. Brackmann, I. Scharrer, T. Abshire, 2000, Thrombosis and haemostasis.

Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose‐formulated recombinant factor VIII

E. Gorina, G. Lemm, N. Bajwa, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A

M. Ragni, H. Brackmann, I. Scharrer, 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

Psychometric evaluation of a patient‐reported symptom assessment tool for adults with haemophilia (the HAEMO‐SYM)

P. Giangrande, J. Wasserman, A. Rentz, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Cross‐cultural development and psychometric evaluation of a patient‐reported health‐related quality of life questionnaire for adults with haemophilia

M. Bullinger, R. Klamroth, W. Schramm, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A

H. Stass, A. Luk, E. Gorina, 2008 .

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

H. Stass, A. Luk, E. Gorina, 2008, Journal of thrombosis and haemostasis : JTH.

P. Larson, W. Schramm, A. Rentz, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy

H. Brackmann, I. Scharrer, T. Abshire, 2000, Thrombosis and Haemostasis.

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A

C. Rothschild, J. Gill, P. Larson, 2005, Thrombosis and Haemostasis.

Stability, efficacy, and safety of continuously infused sucrose‐formulated recombinant factor VIII (rFVIII‐FS) during surgery in patients with severe haemophilia

H. Stass, A. Lubetsky, B. Ravid, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

M. Morfini, P. Collins, A. Faradji, 2008 .

Stability of full‐length recombinant FVIII formulated with sucrose during continuous infusion using a mini‐pump infusion device

P. Larson, E. Gorina, E. Kellermann, 2005, Journal of thrombosis and haemostasis : JTH.

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting

A. Iorio, J. van der Meer, T. Lambert, 2007, Thrombosis and Haemostasis.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

R. Sussman, S. Sahn, S. Nathan, 2014, The New England journal of medicine.

PLN-74809, A Dual αVβ6/αVβ1, Oral, Selective Integrin Inhibitor, Is Well Tolerated and Reduces Lung TGF-β Activity in Healthy Volunteers

S. Turner, K. Leftheris, S. Wong, 2020 .

Dual aVß6/aVß1 inhibitor PLN-74809 blocks multiple TGF-ß activation pathways associated with IPF

S. Turner, L. Hooi, Jianfeng Wu, 2019, Idiopathic interstitial pneumonias.

Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease

S. Nathan, D. Spirig, M. Glassberg, 2016 .

Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity

W. De Backer, C. V. Holsbeke, J. Backer, 2018, Respiratory Research.

Automatic quantitative fibrosis scores at baseline is a predictor of progression in patients with IPF

J. Goldin, Peiyun Lu, G. Kim, 2017 .

Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF

J. Goldin, Peiyun Lu, G. Kim, 2017 .

PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients

G. Raghu, J. Goldin, K. Flaherty, 2017 .

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

G. E. Blouse, U. Simonsson, E. Gorina, 2023, Advances in therapy.

Effect of pamrevlumab on the UCSD-SOBQ (University of California San Diego–Shortness of Breath Questionnaire) in patients with Idiopathic Pulmonary Fibrosis (IPF)

J. Swigris, T. Neff, E. Gorina, 2018, Idiopathic interstitial pneumonias.